The National Institute of Neurological Disorders and Stroke (NINDS), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and the National Institute of Child Health and Human Development (NICHD) encourage applications for the exploratory/developmental program for translational research in muscular dystrophy.*
The muscular dystrophies are progressive, degenerative disorders affecting skeletal and cardiac muscle. Despite substantial research efforts, there are few therapies that are effective in even slowing the course of the disorders. The purpose of this announcement is to exploit the accumulated knowledge of the genetic basis and pathogenic mechanisms in the muscular dystrophies to design and test treatments with potential for reducing the clinical burden of disease.
Areas of research interest include, but are not limited to: development of drug-based therapies to protect muscle mass; development of strategies to enhance existing muscle repair mechanisms; optimizing cell-based muscle replacement strategies; developing, testing, and improving strategies for gene replacement therapy; developing and testing genetic modification therapies to bypass inherited mutations; and developing combination therapies that rely on more than one of the strategies listed above in order to produce a more effective treatment than may be possible with any single strategy.
For more information, potential applicants should contact Dr. John Porter, Program Director, Channels, Synapses, and Circuits Cluster, NINDS, Neuroscience Center, 6001 Executive Boulevard, Room 2142, Bethesda, MD 20892; telephone: 301-496-1917; fax: 301-402-1501; e-mail: firstname.lastname@example.org.
*For a more detailed description of this announcement, please visit the NIH web site at: http://grants.nih.gov/grants/guide/pa-files/PAR-06-203.html.